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 Ocrelizumab phase II trial extension data has 18-month post-drug follow-up. 
 Annualized relapse rate seems to remains low during the drug-free follow-up.  
 Infections and adverse events seem to be reduced during drug-free follow-up 
 Extended interval dosing may be possible that maintains efficacy and allows for more 
successful vaccination to new infections 
 Extended interval dosing may afford a drug-free pregnancy 
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Objective: Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. 
Based on potential similar memory B cell depletion mechanisms with cladribine and 
alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a 
duration of response exceeding the current licenced treatment interval. 
Methods: Internet-located information from regulatory submissions and meeting reports relating 
to the unpublished open-label, phase II ocrelizumab extension trial (NCT00676715) were 
reviewed. This followed people (54-55/arm) with MS, who switched from placebo or interferon-
beta to ocrelizumab for three 600mg treatment cycles (week 24, 48, 72) or people treated with 
ocrelizumab for four 600mg treatment cycles (week 0-72), followed by an 18 month treatment-
free period. 
Results: CD19+ B cells were rapidly depleted within 2 weeks and slow CD19+ B cell repopulation 
began about 6 months after the last infusion with median-repletion of over 15 months. The 
reduced annualized relapse rate during the published efficacy study appeared to be maintained in 
the extension study and there were no new T1 gadolinium-enhancing or T2 lesions detected in 
the treatment-free period. Importantly, within these extension cohorts, there appeared to be 
fewer adverse events and infections events.  
Conclusions:  Ocrelizumab appears to induce durable relapsing disease inhibition, within 3 
treatment cycles Therefore, it may be possible to reduce the frequency of dosing to maintain 
efficacy, whilst limiting infection and other risks associated with continuous immunosuppression 
and could allow more effective vaccination against new pathogens. Further studies are now 
clearly required to determine whether this data is robust, as few people seemed to complete the 
study.  
  




Multiple sclerosis (MS) is the major demyelinating disease of the central nervous system. 
Although considered to be a T cell-mediated disease, CD20 B cell–depleting antibodies exhibit 
high efficacy in MS (1-3). Indeed, we have suggested that agents that inhibit relapsing MS all 
target memory B cell populations (4-6). These may act directly on B cells or may target T cells 
indirectly through loss of B cell help for T cells (1, 4, 7, 8). Although the B cell subset depletion 
potential of ocrelizumab has yet to be fully reported, ocrelizumab and rituximab potently deplete 
memory B cells (1,7,9). Efficacy of CD20-depletion develops within a few weeks of treatment-
onset and is typically administered in 6 monthly cycles to permanently deplete CD19+ B cell 
populations, which includes memory B cells (1,3,7,10). However, memory B cell depletion can 
last for years following treatment, probably due to their slow repopulation kinetics (7, 11). This 
suggests that there may be durable efficacy beyond 6 months, as suggested from studies with 
rituximab (1). Furthermore, marked memory B cell depletion appears to be a common 
mechanism contributing to the efficacy of alemtuzumab and cladribine (5,6). These are 
considered immune-reconstitution therapies with long-term efficacy from a short-term treatment 
cycle (12-14), so we hypothesized that ocrelizumab could similarly induce benefit extending 
beyond a six-monthly treatment cycle. 
This is important, because while ocrelizumab use has been well-tolerated in MS (3), B cells form a 
central part of immunity. As such, continuous B cell depletion is associated with eventual 
hypogammaglobulinaemia creating an increased risk of infection and reduced vaccination efficacy 
(14-17). These risks appear to be significant, as the development of ocrelizumab was terminated 
in other CD20-responsive autoimmunities because of infection-related fatalities adversely 
affecting the risk: benefit balance (18). It is therefore important to determine whether efficacy 
can be maintained and complications de-risked by reduced-frequency dosing. This strategy is 
currently being tested in natalizumab with a view to reduce the risk of developing progressive 
multifocal leucoencephalopathy (19). Furthermore, preliminary studies with rituximab may 
suggest that dosing to memory B cell population kinetics can reduce dosing frequency whilst 
maintaining efficacy (20) 
Despite policies to make trial-data available, trial-information presented at major international 
conferences are not always followed by peer-reviewed publications (5, 21). Therefore, 
information cannot easily be searched or interrogated by internet engines and fails to become 
common knowledge and perhaps allows people to be unwittingly exposed to unnecessary safety 
issues (21). Although the phase II (NCT00676715) and phase III (NCT03599245) ocrelizumab 
efficacy MS studies are published (2,3), the extension study data remain unpublished, except in 
abstract form (22-24). Whilst the phase III extension study examined the influence of 6-monthly 
dosing (24), the phase II extension study followed people during an 18 month treatment-free 
period (22,23). This suggests that clinical benefits are maintained for some time after treatment 
cessation, which may have risk:benefit implications.  
 
         
5 
 
METHODOLOGICAL APPROACH  
Data Analysis: Information on the phase II ocrelizumab trial extension studies have been 
presented from 2012 onwards (22,23). Through meeting abstracts, posters and regulatory 
documents available on the internet, we were able to determine the key trial results. Data was 
extracted, with the assistance of WebplotDigitizer V4.1 (https://automeris.io /WebPlotDigitizer. A 
Rohatgi) and a facsimile of presented data is reported. Attempts to verify these data with 
Freedom of Information requests submitted to the European Medicines Agency (5) were 
unsuccessful. However, access to a redacted copy of the WA21493 clinical study report March 
2016, with data cut-off January 2015 (25), was supplied via the clinicaltrialsdatarequest.com 
portal. 
Trial Design: Details of the phase II placebo-controlled, randomised double-blind trial 
(NTC00676715) of placebo, beta-interferon-1a (IFNβ. 30µg Avonex® administered 
intramuscularly once a week) and two doses of ocrelizumab and the demographics and numbers 
of participants have been published (2,22). In brief, this included the requirement to have had 
two documented relapses or ≥1 relapse and ≥ 6 T2 lesions within the year prior to screening and 
to have an EDSS of 1.0-6.0 (2). Likewise, the methods and outcomes of the 24 week blinded trial 
have been reported (2). In brief, people with MS (pwMS) were randomised to either: (a) two 
placebo intravenous infusions at 15 day intervals (b) two infusions of 300mg ocrelizumab at 15 
day intervals (600mg dose), with infusion reaction prophylaxis, and (c) open-label 30μg IFNβ 
administered twice a week (2). An additional group of people, not discussed here, received two 
doses of 1000mg ocrelizumab (2). After 24 weeks all groups (a-c) received ocrelizumab, which 
was administered at weeks 24, 48 and 72. People treated with placebo and IFNβ initiated their 
ocrelizumab treatment with two doses of 300mg ocrelizumab; all subsequent doses were single 
infusions of 600mg at six-month intervals consistent with the subsequent phase III trial (3) and 
the current labels in the United States and Europe (26,27). These dosing schedules induced 
comparable levels of T and B cell depletion (28,29). Those pwMS receiving high dose (1000mg) 
ocrelizumab received a single 1000mg infusion at weeks 24 and 48 and 600mg at week 72 
(22,23). Only data related to the 600mg licenced dose (26,27) are reported here.  The treatment 
response was monitored to week 96 at which time people entered a treatment-free extension 
period for examination of a safety follow-up over 24 weeks and a B cell monitoring period up to 
week 144, where pwMS were assessed every 12 weeks until repletion, defined as a return to the 
baseline CD19 count or the lower limit of normal, occurred (22). PwMS who discontinued the 96 
week-treatment period also underwent the treatment–free, safety follow-up period (Table 1). 
Safety and efficacy were assessed throughout the study via regular neurological and physical 
examination (2,22).   
  




The phase II study consisted of a screening period, where 273 pwMS were assessed for eligibility 
and 220 were entered into randomisation. Fifty-four pwMS were treated in the placebo arm, 54 
pwMS in the IFNβ arm and 55 pwMS in each of two ocrelizumab arms (22). All pwMS in the 
placebo arm, 94% on IFNβ and 93% on 600mg ocrelizumab infusions completed the phase II 
efficacy study (22). In these three arms, 151 (93%) pwMS chose to enter the open-label 
extension study to receive ocrelizumab from week 24-96 and 133 (82%) pwMS subsequently 
entered the treatment-free follow-up period (Week 96-144), which also acquired data from 
people who had withdrawn from the study during earlier cycles. The follow-up study from week 
96-144 provided time to monitor B cell repopulation.  140 people completed 96 weeks and the 
safety follow-up to 120 weeks (22).  However, relatively few people (n=33) were reported to 
have week 144 data, and therefore, caution must be applied when viewing the results (22). This 
was due to the on-going nature of the trial at the time of data presentation (22). However, it has 
been determined that actually 101 people within the 3 groups completed the treatment-free 
study to 144 weeks (25). At which time they resumed ocrelizumab treatment (25). 
Analysis of lymphocyte subsets indicated that ocrelizumab induced a rapid and marked depletion 
of CD19+ B cells within two weeks, and maintained a nadir state for the initial 24 week phase II 
efficacy study and the 96 week extension study following switching of placebo and IFNβ-treated 
to 600mg infusions of ocrelizumab (Figure 1A). Slow CD19+ B cell repopulation began about 6 
months after the last infusion (Figure 1A). The median time to B cell repletion, defined as the 
time taken to reach baseline levels or lower limit of normal, was 62 weeks (95%CI 60-72 
weeks)/placebo arm receiving 3 ocrelizumab cycles and 71.9 weeks (95% CI 62.3-75.7 in the 
arm receiving 4 ocrelizumab cycles (22,23,25,28). This had occurred in a median of 70% of 
pwMS following 3 cycles and 52% of pwMS following 4 cycles ocrelizumab by week 144 (22,23), 
(Figure 1B). The duration to repletion ranged from 27-175 weeks (25,26,28). Depletion and 
repopulation of B cell subset data was not reported (22,23). However, based on studies with 
rituximab, we would anticipate that repopulation of memory B cells would take significantly longer 
than apparent CD19 B cell repletion, which is largely driven by repopulation of immature/mature 
B cells (1,7). A small fraction of people appeared not to deplete adequately in those receiving less 
than 2 cycles of ocrelizumab (Figure 1B).  Whether this relates to polymorphisms influencing 
antibody-dependent cell cytotoxicity remains to be established. Examination of CD4 and CD8 T 
cell and natural killer cell levels demonstrated very little change although there was a transient 
drop following the initial infusion of ocrelizumab (Figure 1C). This was not really evident when 
placebo and IFNβ arms were switched, as bloods were only collected 12 weeks after infusion 
(Figure 1C). These are consistent with effects reported in phase III studies (30).   
The phase II trial demonstrated a significant (p=0.0019) reduction in the adjusted annualised 
relapse rate between placebo and ocrelizumab treatment from 0.557 (n=54) to 0.127 (n=55) at 
the 48-week analysis period after one treatment cycle (2) (Table 1, Figure 1D). In addition to a 
relatively quiescent clinical picture, magnetic resonance imaging of the brain revealed no new T1 
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gadolinium-enhancing (Figure 1E) or T2 lesions in 36 pwMS having undergone imaging (22,23). 
The proportion of pwMS with confirmed 6-month disability progression remained low in all groups 
treated with ocrelizumab (22,23) (Figure 1F). Although treatment was not infallible and relapses 
occurred, efficacy appeared to be maintained through 3-4 treatment cycles of treatment of the 
extension study and the year-long safety and B cell monitoring period (Figure 1D. Table 1). The 
data presented in meeting reports (22,23) (Table 1), was consistent with the analysis of the 
complete cohort (n=101), finishing the study to week 144 (25). This latter source indicated that 
the adjusted annualized relapse rate over 96-144 week was actually 0.058 (95% confidence 
interval (CI) 0.028-0.120. Ocrelizumab group), 0.073 (95% CI 0.037-0.144) in the placebo-
ocrelizumab group) and 0.065 (95% CI. 0.031-0.136) in the interferon-ocrelizumab group (25). 
Therefore, 3-4 cycles of 600mg ocrelizumab seems to induce disease inhibition that is durable for 
at least 12 months, suggesting a long-term benefit from a short-term treatment cycle. 
The safety issues related to 2 years of ocrelizumab treatment have been addressed within the 
phase III clinical trial programme involving 827 people with relapsing MS randomised to receive 
six-monthly 600mg ocrelizumab dosing (3). However, within the phase II study cohort, 60.0-
71.7% of people experienced adverse events and 1.8-6.0% experienced serious adverse events 
and 28.0-43.6% of people experienced infections during the six months of ocrelizumab treatment 
in the three 600mg ocrelizumab arms (22), (Table 2). This compared 15.2-26.1% of people 
experiencing and adverse events and 0-2.2% of people experiencing a serious adverse event in 
the last 6 months of the treatment free period in the three treatment arms and 6.3-10.9% of 
people experienced and infection (22), (Table 2). Whilst must be viewed cautiously due to fewer 
participants completing the study at the time of initial analysis (22), examination of the frequency 
of these events for the last year of the extension period in analysis of the whole cohort finishing 
the drug free extension period (25), is perhaps lower than the first 6 months of treatment (Table 
2). This may suggest that there were more adverse events and infections during the first 24 
weeks of treatment than during the last 24 weeks of the treatment free period (Table 2). 
However, some individuals are likely to be more susceptible to adverse events and may drive up 
AE frequency early on. Importantly, there were fewer pwMS completing the 120-week study than 
entered the extension study and therefore those remaining within the study may be selected for 
responding well to treatment. This could account for the magnitude of reduced adverse events 
during the treatment-free period originally reported (22), but suggests potential benefit from 
avoiding drug treatment (Table 2). Perhaps adverse events should have increased as 
hypogammaglobulinemia and increased susceptibility to infection normally may develop over time 
(14,16). However, during the phase II study IgG responses were relatively stable, but the levels 
of immunoglobulin M (IgM) appeared to be slightly reduced (25). Prior to treatment IgM levels 
were 1.02 ± 0.52 g/L (n=97) in a group of individuals and were 0.92 ± 0.46 g/L (24 weeks. 
n=49), 0.85 ± 0.46g/L (48 weeks. n= 36) and 0.80 ± 0.32g/L (96 weeks. n=11) in the 
treatment-free cohort (25). Levels of immunoglobulin G were 10.30 ± 2.41 g/L (n=97) prior to 
treatment and were 9.99 ± 2.46 g/L (24 weeks. n=49), 9.50 ± 2.50g/L (48 weeks. n= 36) and 
9.27 ± 2.21g/L (96 weeks. n=11) (25). This trend is consistent with the phase III extension 
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studies where IgM reduced levels reduced by 56.3% (1.37 to 0.64g/L) compared to 21.3% (2.13 
to 1.74g/L) for IgA and 17.0% (10.53 to 8.79 g/L) for IgG over 264 weeks of ocrelizumab 
treatment (16). Whilst these effects may have been limited by the influence of a “drug holiday”, 
these elements will only be elucidated through larger follow-up studies.  
DISCUSSION 
This study suggests that ocrelizumab may be a selective immune-reconstitution therapy, with a 
long-term efficacy from a short-term treatment cycle. As such, it was found that 12-18 months 
after the last infusion of 3 cycles of 600mg ocrelizumab, the levels of disease activity appear to 
be similar to that seen in the phase III extension studies following 6 cycles of ocrelizumab (22-
24). However, caution is needed when comparing different studies and given the low numbers of 
people involved in this study. This sustained treatment-effect comes with the apparent benefit of 
a reduced risk of serious infection, whilst being treatment-free.  There appeared to be fewer 
adverse events in the 6 months at the end of the treatment-free period (week 120-144) 
compared to the first six months. This is unsurprising as infusion reactions were a common 
adverse event (2). This occurs in about 34% (n=283/825) of people with relapsing MS and 
probably relates to the lytic cell syndrome that occurs due to antibody-mediated killing of cells 
(30). The frequency of these reactions appeared to be reduced by the second cycle of antibody 
administration, although still present in about half (n=106/227) of the people demonstrating 
infusion reactions on first cycle (30). This is perhaps consistent with the finding that many people 
will have fewer circulating B cells when retreated. However, adverse events still remain higher 
than during the treatment-free period suggesting, with caveats, that it may be possible to reduce 
the risk:benefit balance by reduced dosing frequency. 
The phase I extension study of rituximab (2000mg/cycle) in MS also reported maintained benefit 
12 months after the last infusion (1). Similarly, a single dosing cycle of 1000mg rituximab 
followed by maintenance regime of daily glatiramer acetate showed treatment failure (>2 new 
lesions, relapse or accumulated disability) in 10/27 (37%) pwMS, with a median time to failure of 
23 months (lower 95% confidence limit 14.6 months) in a 36-month follow-up (29). It remains to 
be seen if this would have any additional benefit over rituximab monotherapy.  In addition, off-
label studies with rituximab, where treatment was halted, demonstrated long-acting benefit and 
an absence of rebound disease activity phenomena after stopping therapy (31). It is currently not 
clear whether ocrelizumab will have a longer treatment response, as it has more effective 
depletion characteristics than rituximab (1,28,32).  As such, it was found that 20% people began 
to repopulate by 6 months (32), whereas only 5% pwMS began to repopulate within 6 months 
after ocrelizumab and CD19 repopulation took longer than 1 year (26,28). Importantly, this 
repopulation will be driven by immature/transitional and mature B cells emanating from the bone 
marrow, as a stereotyped B cell repletion characteristic (1,11).  
Given the marked B cell depletion, as probably expected, vaccination with a variety of different 
antigens started about 3 months after infusion, attenuated humoral responses (Table 3. See 
NCT02545868 for results). However, vaccinations responses were not absent, suggesting that 
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surviving/repopulating immature/mature B cells may be able to provide some protection from 
new infections. As such, although the risk of some infections may be elevated, this is not marked 
(3, 16, 28). The memory B cell compartment that may harbour the key pathogenic cells, will 
likely remain depleted for very much longer, as shown following a single rituximab administration 
(7, 11).  
The influence of ocrelizumab on individual B cell subsets during the trials is currently unreported, 
but it maintains all CD19 B cell subsets in a nadir state (3) and its effects on B cell subsets is 
consistent with the type of response reported following rituximab treatment (7,9). The longevity 
of the treatment response beyond repopulation of total CD19+ cells shown here, is consistent 
with other B memory cell targeting, immune-reconstitution therapies in MS (5,6,12). However, it 
remains to be seen whether therapy of relapsing MS actually relates to depletion of memory B 
cells, as recently suggested (20), as appears to occur in some other CD20-responsive 
autoimmunities (4,9,11).  It is known that rituximab can deplete memory B cells for over 12 
months in MS and that a substantial depletion is still evident 2-3 years or longer in other CD20-
responsive autoimmune diseases (7,11). This type of slow repopulation, as seen in the blood, 
may relate to the durable, yet reversible disease control following a single infusion cycle (33). 
However, it should be remembered that relapses can develop despite lack of detection of 
peripheral blood memory B cells, indicating that an important B cell compartment is elsewhere 
(11,32). Further study is required to determine whether and when disease breakthrough occurs 
after a limited number of cycles of ocrelizumab. Occurrence of disease break-through will 
determine whether ocrelizumab is thus like other continuously-delivered immunotherapies or 
whether long-term disease control is seen, as found in people treated with current T and B cell 
targeting, immune-reconstituting therapies (12-14).  
While response to therapy is more consistent with a B cell-directed mechanism of action and the 
hypothesis for the importance of targeting memory B cells to control relapsing MS (3,4,11). 
However, to support a T cell-centric view of MS pathogenesis, it has been suggested that the 
activity of rituximab and ocrelizumab could be related to the depletion of CD20+ T cells, which 
represent <5% of the total T cell population (7,8,34). However, the influence of ocrelizumab on T 
cell numbers was relatively marginal, as shown here, and during the phase III studies, CD4+ cells 
decreased by 0.8% and CD8+ T cells decreased by 8.6% after 96 week of treatment in relapsing 
MS (23,24,29). This suggests that it is unlikely to account for the high efficacy of ocrelizumab. 
This is further indicated by the fact that marked CD4 T cell depletion had limited influence on 
relapsing MS (35) and importantly that, whilst T cells do not express significant levels of CD19 
message or protein, CD19-B cell depleting antibodies also reduce the formation of active MS 
lesions in a manner similar to CD20-depleting antibodies (34,36). Although a relative increase in 
T regulatory cells may contribute to efficacy (8), the slow increase may not correspond well to the 
rapid clinical response (8, 10).  
Only a small amount of antibody may enter the central nervous system and as CD20 is not 
expressed by plasmablasts and plasma cells, the role of ectopic B cell follicles in relapsing MS is 
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not yet clear (11,37). As such, B cells and oligoclonal immunoglobulin bands in the cerebrospinal 
fluid persist, at least after rituximab administration (11, 38).  However, increasing exposure may 
be associated with limiting the accumulation of progressive disability, possibly indicating that CNS 
penetration of antibody could contribute to efficacy (39). However, B cells may act as essential 
antigen presenting cells that activate pathogenic T cells or they may target oligodendrocytes or 
nerves to participate directly in the pathogenesis of MS (4,8).  
If there is a durable activity of CD20-depletion, as seen with other immune-reconstitution 
therapies (12,13), ocrelizumab would have enhanced utility in the management of MS because of 
its relatively lower side-effect profile and limited monitoring requirements, compared to other 
high-efficacy treatments (14). This could also lead to cost-effectiveness improvements that may 
help improve access to treatment, in particular to the primary progressive MS indication, where 
concerns about the cost-effectiveness has led to limitations to treatment (40). However, even if 
ocrelizumab is simply an agent that requires repeated treatments, lower frequency administration 
will have benefits for pwMS as it may help avoid serious infectious complications (15,16). Studies 
with rituximab in MS and other autoimmune conditions have indicated that through B cell 
monitoring, it may be possible to extend dosing intervals without loss of efficacy (9,11,20,41). 
Further studies are required to determine whether adaptive ocrelizumab dosing based on B cell 
counts can be of value in MS. 
Thus, it may be possible to develop and exploit extended interval dosing interval studies that 
allow therapeutic benefit to be maintained, whilst allowing immature B cells to recover more. As 
these cells are precursors for novel immune responses, it may allow a more effective vaccination 
response, such as against SARS-CoV-2, than currently occurs (17) (Table 3). In addition, an 
extended 12-18 month, or potentially longer, treatment-free period could provide sufficient time 
for a drug-free pregnancy, whilst under ongoing protection from disease activity. Ocrelizumab has 
an elimination half-life of about 26 days (26-28) meaning the CD20-depletion potential probably 
remains for many months after infusion (2 x 300mg dose) as less than a thirtieth of the clinical 
dose remains potently B cell depleting (42). B cells form within foetal liver by 9 weeks and 
circulate from 12 weeks from conception (43). Therefore, transplacental passage of antibody can 
lead to foetal and neonatal B depletion (44). To avoid this issue, effective contraception is 
advised for 6-12 months, depending on region, after the last dose of ocrelizumab (26,27). Whilst 
CD20-depletion of pregnant women and foetal B cell depletion has been tolerated and neonatal 
depletion was transient after birth, post-partum maternal relapses have been documented 
following B cell depletion (26,27). Therefore, further studies to confirm the safety, the optimal 
number of treatment-cycles and the longevity of disease inhibition during pregnancy are required 
to determine whether acceptable levels of disease control are possible and whether there is a 
similar or longer duration of activity than that found with rituximab treatment (1,33).   
Although ocrelizumab is humanised to potentially reduce the frequency of binding (0.4% in 96-
week phase III trial N=3/807 (3) and neutralizing antibodies (0.1% in phase III trial. N=1/807 
(3)) seen with chimeric antibodies (28.6% at week 48 in the phase I rituximab trial (1), these are 
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also controlled by dose (41). As such, 20mg (2 x 10mg) ocrelizumab infusion induced 
ocrelizumab-specific antibodies in about 19% (n=7/36 to 72 weeks) of people compared to 0% 
(n=0/40 per group) of people treated with 2 x 200mg or 2 x 500mg ocrelizumab (42). Therefore, 
it would be important to ensure that reduced-dosing does not allow neutralizing antibodies to 
develop as antibody levels taper and immature B cells repopulate, which could reduce the 
pharmacodynamic effect of the drug. 
The data presented here suggests that head to head studies of limited-dosing ocrelizumab, 
versus current standard, repeated-dosing of ocrelizumab and limited-dosing ocrelizumab versus 
alemtuzumab or cladribine treatment, are warranted. This would determine whether there is 
safety and cost-effectiveness benefit of extended dosing, as the lower numbers completing the 
studies may have skewed the positive effects. Alternatively, it may help to determine whether the 
additional T cell depleting capacities of cladribine and alemtuzumab, provides additional benefit 
that may contribute to long-term disease control of these immune reconstitution therapies (5,12).  
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Phase II OLE 
Phase II OLE 
 
Phase II OLE 
Phase II OLE 
Phase II OLE 
First 24 weeks (0-24) 
First 24 weeks (0-24) 
First 24 weeks (24-48)  
First 24 weeks (24-48)  
 
Last 24 weeks (120-144)  
Last 24 weeks (120-144)  







































Phase III OLE 
 
Phase III OLE 
Phase III OLE 
 
Phase II OLE 
Phase II OLE 
First 48 weeks (0-48) 
First 48 weeks (0-48) 
First 48 weeks (96-144) 
  
Last 48 weeks (192-240)  
Last 48 weeks (96-144) 
 
Last 48 weeks (96-144)  














Data on the reported adjusted annualised relapse rate (aARR) were extracted from meeting reports (22,23) 
relating to the phase II and the phase II open label extension (OLE) following treatment with ocrelizumab 
(Week 0-96. N=51-46), placebo (Week 0-24. N=54) switching to ocrelizumab (week 24-96 N=51-48) or 
twice weekly interferon beta (week 0-24. N=51) switching to ocrelizumab N=49-46), and the phase III 
(OPERA I & OPERA II following treatment with interferon beta N=829 and ocrelizumab (N=827) and the 
phase III OLE extension study following people treated with ocrelizumab (n = 702) or Beta interferon (Week 
96-240. N=702-570). Probability compared ocrelizumab to placebo (phase II) or interferon beta (phase III) 
studies (2, 22-24). 
 
 
Table 2  
Reduced infections during the drug-free treatment period in the ocrelizumab phase II extension 
trial 
 
Treatment Analysis Serious/Adverse Events Serious/Infection 










1.9%/34.0%   
 
0.0%/43.6%      
Ocrelizumab* Second 24 weeks 2.0%/50.0% 1.8%/54.0% 0.0%/12.0% 2.0%/36.0% 
      




Last 24 weeks 
 















Data relating to the frequency of adverse events/serious adverse events and infections/serious infections 
following treatment with four six-monthly cycles of 600mg ocrelizumab (week 0-96) or after an infusion of 
placebo (week 0-24) followed by three cycles ocrelizumab. This was followed by an 18-month treatment free 
period (week 96-144). Results from the last 24 weeks of the study represent weeks 120-144 of the open 
label extension study (22). The beta interferon group was not analysed to avoid any influence of 
immunomodulation by the treatment. * Data from the meeting report 2012. ** Data from the clinical study 
report 2016. 
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Table 3. Ocrelizumab inhibits vaccine responses 
 Seroconversion after 4 weeks 








Pneumococcal PVV-23 Serotype 1 
Pneumococcal PVV-23 Serotype 2 
Pneumococcal PVV-23 Serotype 3 
Pneumococcal PVV-23 Serotype 4 
Pneumococcal PVV-23 Serotype 5 
Pneumococcal PVV-23 Serotype 6B 
Pneumococcal PVV-23 Serotype 7F 
Pneumococcal PVV-23 Serotype 8 
Pneumococcal PVV-23 Serotype 9N 
Pneumococcal PVV-23 Serotype 9V 
Pneumococcal PVV-23 Serotype 10A 
Pneumococcal PVV-23 Serotype 11A 
Pneumococcal PVV-23 Serotype 12F 
Pneumococcal PVV-23 Serotype 14 
Pneumococcal PVV-23 Serotype 15B 
Pneumococcal PVV-23 Serotype 17F 
Pneumococcal PVV-23 Serotype 18C 
Pneumococcal PVV-23 Serotype 19A 
Pneumococcal PVV-23 Serotype 19F 
Pneumococcal PVV-23 Serotype 20 
Pneumococcal PVV-23 Serotype 22F 
Pneumococcal PVV-23 Serotype 23F 
Pneumococcal PVV-23 Serotype 33F 
Response to ≥ 2 serotypes 































































People with multiple sclerosis were infused with 300mg ocrelizumab on day 0 and 15 or were 
untreated and were vaccinated 4 weeks after ocrelizumab infusion.  The results show the 
frequency of seroconversion within 4 weeks after vaccination in untreated people (n=34/group) 
or people treated with ocrelizumab following injection with tetanus toxoid (n=68), pneumococcal 
PPV-23 (n=66-68) or influenza vaccines (n=35). Seroconversion to tetanus toxoid represents a 
titre ≥ 0.2IU/ml from a baseline of <0.1IU/ml or at least a 2-fold increase for people with 
baseline titre≥ 0.1IU/ml at 4 weeks or at least a 4-fold increase for people with baseline titre ≥ 
0.1IU/ml. A 23-PPV vaccine response against a serotype was defined by a 2-fold increase in anti-
pneumococcal antibody of >1µg/ml compared with pre-vaccination levels, following Food and 
Drug Administration guidance. Seroconversion of haemagglutination inhibition titre from <10 at 
baseline to ≥ 40 or if the baseline titre was ≥ 10 at least a 4-fold increase in haemagglutination 
inhibition titre, following   haemagglutination inhibition. Results and experimental details 










Inhibition of CD19 B lymphocytes by ocrelizumab. PwMS were randomised to 1 cycle (inverse 
triangles) of intravenous placebo (n=54), intramuscular interferon beta 1a (n=54) or 600mg 
intravenous ocrelizumab (n=55) followed by 3 six-monthly cycles (inverse triangles) of 600mg 
ocrelizumab and a treatment-free period from week 72. (A) The median absolute number of 
peripheral blood CD19+ B cells was assessed by flow cytometry (B) The median time taken to 
CD19+ B cell repletion, defined as the time taken to reach baseline levels or lower limit of normal 
from the last infusion. (C) The mean absolute number of peripheral blood CD4+ or CD8+ T cells 
and CD56+ natural killer cells assessed by flow cytometry. (D) The adjusted (by geographical 
region) annualized relapse rate mean during the trial 0-24wk, the trial extension period between 
week 24-96, the whole treatment-free follow-up between week 96-144wk and the B cell repletion 
study during week 120-144, (E) The mean number of T1 gadolinium-enhancing lesions detected 
by magnetic resonance imaging during the placebo-controlled trial period for placebo  (n=54), 
IFNβ (n=52) and 600mg ocrelizumab (n = 51) and for the treatment-free safety follow-up 
between week 96-144 (n=36) following 4 cycles of ocrelizumab (F) The proportion of people with 
6 month confirmed disease progression assessed by worsening of the Expanded Disability Status 
Scale based on the intention to treat population. The results are a facsimile of those presented 
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FIGURE 1.  
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